What is Rapport Therapeutics, Inc.'s offering costs?

Rapport Therapeutics, Inc. (RAPP) reported offering costs of $180K in Q1 2026.

What does offering costs mean?

Includes direct costs incurred in connection with equity or debt offerings, such as legal, accounting, and printing fees that are not otherwise netted against proceeds. Monitoring these costs is important for evaluating the efficiency of the company's capital-raising activities. High offering costs relative to proceeds may indicate inefficient financing execution.

Rapport Therapeutics, Inc. RAPP Offering Costs

Offering Costs at other companies

Lightpath TechnologiesLPTH

$550K—

MidCap Financial Investment CorporationMFIC

$300K—

Golub CapitalGBDC

$288.04M—

Cal-Maine FoodsCALM

$1.7M—

ImmunomeIMNM

$364K-96.5%

Dyne Therapeutics, Inc.DYN

$106K—

Other financials

Income statement

See full

Revenue$20.0M—

Operating income-$24.2M+10.7%

Net income-$19.9M+17.5%

EPS (diluted)-$0.42+38.2%

Balance sheet

See full

Cash & equivalents$78.1M+35.5%

Total debt$10.8M+37.8%

Total equity$471.5M+65.0%

Total assets$497.6M+64.7%

Cash flow

See full

Operating cash flow-$13.1M+35.5%

CapEx$86.0K-70.4%

Free cash flow-$13.1M+36.0%

Valuation

See full

Market cap$1.91B+380%

Enterprise value$1.85B+429%

Returns & leverage

See full

Return on equity-28.3%—

Debt / equity0×0.0×

Current ratio27.1×-3.9×

Where this comes from

Reported directly by Rapport Therapeutics, Inc. in its filing.

Tagged under the XBRL concept rapp:OfferingCosts.

The official record: Rapport Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Rapport Therapeutics, Inc.'s offering costs.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Rapport Therapeutics, Inc.'s offering costs?: Rapport Therapeutics, Inc. (RAPP) reported offering costs of $180K in Q1 2026.
What does offering costs mean?: Includes direct costs incurred in connection with equity or debt offerings, such as legal, accounting, and printing fees that are not otherwise netted against proceeds. Monitoring these costs is important for evaluating the efficiency of the company's capital-raising activities. High offering costs relative to proceeds may indicate inefficient financing execution.